Earnings

Vimta Labs consolidated net profit rises 0.66% in the June 2024 quarter

Vimta Labs Consolidated March 2023 Net Sales at Rs 81.82 crore, up 10.44% Y-o-Y

Buzzing stocks: Laurus Labs, Bharti Airtel, Godrej Consumer, Mukund, ABB India, Adani Wilmar, Anupam Rasayan India, Bajaj Consumer Care, Cholamandalam Investment, Godrej Properties, Havells India, Reliance Power, Sula Vineyards, Tata Chemicals, Titan Company, Vimta Labs and Vishnu Chemicals

Stocks to watch on May 3, 2023

GTL Ltd, Add-Shop E-Retail Ltd, Vimta Labs Ltd and Savita Oil Technologies Ltd are among the other losers in the BSE’s ‘B’ group today, 30 January 2023.

Heranba Industries Ltd leads losers in ‘B’ group

Vimta Labs Consolidated December 2022 Net Sales at Rs 77.38 crore, up 14.92% Y-o-Y

Vimta Labs consolidated net profit rises 35.63% in the September 2022 quarter

To invest ₹70 cr to strengthen testing infra

VIMTA Labs forays into electrical, electronics testing

The paid-up share capital of the Company has accordingly increased from Rs. 4,42,15,620 consisting of 2,21,07,810 equity shares having a face value of Rs. 2/- each to Rs. 4,42,35,546 consisting of 2,21,17,773 equity shares having a face value of

Vimta Labs allots 9963 equity shares under ESOP

Vimta Labs’ consolidated net profit surged 44.91% to Rs 11.68 crore on a 14.77% jump in revenue from operations to Rs 67.34 crore in Q3 FY22 over Q3 FY21.

Vimta Labs Q3 PAT grows 45% YoY to Rs 12 cr

Vimta Labs consolidated net profit rises 44.73% in the December 2021 quarter

Vimta Labs standalone net profit rises 44.44% in the December 2021 quarter

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Vimta Labs Limited is engaged in providing testing and contract research services in the fields of clinical and pre-clinical studies, clinical reference, analytical testing, advanced molecular biology and environmental studies.

Vimta Labs Ltd